Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Collaborate on Peptide Studies with Belfast Researchers

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said today that it will collaborate with the Molecular Therapeutics Research Group at the School of Pharmacy, Queen’s University Belfast, to analyze peptides within amphibian venom.
 
The research group is using Thermo Fisher’s LTQ Orbitrap XL mass spectrometer on a trial basis for complex peptide identification and for generating data needed for the de novo sequencing of peptides. The group is currently working on the isolation, structural characterization, and functional evaluation of novel peptides extracted from amphibian, snake, and arthropod venoms.
 
The research, conducted by Chris Shaw and colleagues, is aimed at discovering novel peptide drug discovery leads.
 
Shaw said in a statement that the Orbitrap technology “has enabled us to determine that the synthetic replicate produced in analysis is highly accurate in terms of molecular characterization identical to the natural compound.” He claimed this is the first time a proteomics instrument has been able to achieve this feat, which means that “we can avoid the possibility of working for years on fruitless research.”

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.